Role of CXCR3 ligands in IL-7/IL-7Rα-Fc-mediated antitumor activity in lung cancer

Clinical Cancer Research

Volumn 17, Issue 11, 2011, Pages 3660-3672

  Andersson, Åsa ^a   Srivastava, Minu K ^a   Harris White, Marni ^a,b   Huang, Min ^a,b   Zhu, Li ^a,b   Elashoff, David ^a   Strieter, Robert M ^c   Dubinett, Steven M ^a,b   Sharma, Sherven ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINASE; CD69 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 7 RECEPTOR ALPHA FC FRAGMENT; RECOMBINANT INTERLEUKIN 7; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; LUNG CANCER; LYMPHOCYTE FUNCTION; MACROPHAGE; MEMORY T LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL10; CHEMOKINE CXCL9; IMMUNOGLOBULIN FC FRAGMENTS; INTERFERON-GAMMA; INTERLEUKIN-7; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; RECEPTORS, CXCR3; RECEPTORS, INTERLEUKIN-7; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 79957903880     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3346     Document Type: Article

References (56)

1. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74. (Pubitemid 40488632)
2. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-66. (Pubitemid 30305068)
3. Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS, et al. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 2000;27:27-35.
4. + T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006;94:275-80.
5. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008;26:4410-7.
6. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005;174:6571-6. (Pubitemid 40705615)
7. Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, Spritzler J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood 2001;97:2983-90.
8. Managlia EZ, Landay A, Al-Harthi L. Interleukin-7 signalling is sufficient to phenotypically and functionally prime human CD4 naive T cells. Immunology 2005;114:322-35. (Pubitemid 40314805)
9. Aspinall R, Henson S, Pido-Lopez J, Ngom PT. Interleukin-7: an interleukin for rejuvenating the immune system. Ann N Y Acad Sci 2004;1019:116-22. (Pubitemid 38951294)
10. Freitas AA, Rocha BB. Lymphocyte lifespans: homeostasis, selection and competition. Immunol Today 1993;14:25-9. (Pubitemid 23028247)
11. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood 2002;99:3892-904. (Pubitemid 35332024)
12. Jicha DL, Mule JJ, Rosenberg SA. Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med 1991;174:1511-5.
13. Naume B, Espevik T. Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. J Immunol 1991;147:2208-14.
14. Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 2007;7:144-54. (Pubitemid 46178275)
15. Bradley LM, Haynes L, Swain SL. IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol 2005;26:172-6. (Pubitemid 40312525)
16. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulé JJ, Rosenberg SA, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-72. (Pubitemid 23117076)
17. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5. (Pubitemid 24196166)
18. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-9. (Pubitemid 28150594)
19. Bevan MJ. Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp Med 1995;182:639-41.
20. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998;95:1178-83. (Pubitemid 28124932)
21. Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, et al. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res 2003;63:9007-15. (Pubitemid 38064082)
22. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005;437:141-6. (Pubitemid 41613441)
23. Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O'Carroll K, et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 2001;98:1070-7.
24. Qian G, Bin Wu M, Wu G, Huang S, Yan Y, Tian B, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-16.
25. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol 2004;165:1853-63. (Pubitemid 39578365)
26. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621-67. (Pubitemid 34293436)
27. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008;18:349-55.
28. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6. (Pubitemid 43121975)
29. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12. (Pubitemid 43165918)
30. Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC;10:112.
31. Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol 2007;37:14-6. (Pubitemid 46128780)
32. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005;23:344-6. (Pubitemid 41443435)
33. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55. (Pubitemid 35223554)
34. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007;179:977-83.
35. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996;184:963-9.
36. Belperio JA, Keane MP, Burdick MD, Lynch JP 3rd, Zisman DA, Xue YY, et al. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 2002;169:1037-49. (Pubitemid 34753464)
37. Andersson A, Yang SC, Huang M, Zhu L, Kar UK, Batra RK, et al. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 2009;182:6951-8.
38. Sharma S, Batra RK, Yang SC, Hillinger S, Zhu L, Atianzar K, et al. Interleukin-7 Gene-Modified Dendritic Cells Reduce Pulmonary Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma. Hum Gene Ther 2003;14:1511-24. (Pubitemid 37357739)
39. Komschlies KL, Gregorio TA, Gruys ME, Back TC, Faltynek CR, Wiltrout RH. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function and induces regression of established metastases. J Immunol 1994;152:5776-84. (Pubitemid 24174157)
40. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 1999;155:537-47. (Pubitemid 29370403)
41. Fajardo LF, Prionas SD, Kwan HH, Kowalski J, Allison AC. Transforming growth factor beta1 induces angiogenesis in vivo with a threshold pattern. Lab Invest 1996;74:600-8. (Pubitemid 26105721)
42. Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 2000;165:373-80. (Pubitemid 30429529)
43. Hagenbaugh A, Sharma S, Dubinett S, Wei SH, Aranda R, Cheroutre H, et al. Altered immune responses in IL-10 transgenic mice. J Exp Med 1997;185:2101-10. (Pubitemid 27265994)
44. Hu HM, Urba WJ, Fox BA. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol 1998;161:3033-41. (Pubitemid 28425729)
45. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998;70:83.
46. Johnson LL, Sayles P. Interleukin-12, dendritic cells and the initiation of host-protective mechanisms against Toxoplasma gondii. J Exp Med 1997;186:1799.
47. Ma X, Amezaga AM, Gri G, Gerosa F, Trichieri G. Immunomodulatory functions and molecular regulations of IL-12. Chem Immunol 1997;68:1.
48. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-6.
49. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30. (Pubitemid 23277355)
50. Luster AD, Leder P. IP-10, a CXC chemokine, elicits a potent thymus-dependent anti-tumor response in vivo. J Exp Med 1993;178:1057-65. (Pubitemid 23260444)
51. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996;184:981-92.
52. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997;89:2635-43. (Pubitemid 27172547)
53. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998;161:927-32. (Pubitemid 28323558)
54. Strieter RM, Kunkel SL, Arenberg DA, Burdick MD, Polverini PJ. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun 1995;210:51-7.
55. Sharma S, Yang SC, Hillinger S, Zhu LX, Huang M, Batra RK, et al. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2003;2:22.
56. Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004;10:2891-901. (Pubitemid 38509169)